Description
Recombinant Human Antibody (Apomab) is capable of binding to DR5, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-DR5 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-DR5 proteins mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody induces tumor cell apoptosis through DR5 and investigated the structural features of its interaction with DR5.
Target
DR5
Target Alias Names
TNFRSF10B, tumor necrosis factor receptor superfamily, member 10b, DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLERDR5, tumor necrosis factor receptor superfamily member 10B, Fas-like protein, death receptor 5, cytotoxic TRAIL receptor-2, TNF receptor superfamily member 10b, apoptosis inducing receptor TRAIL-R2, apoptosis inducing protein TRICK2A2B, TNF-related apoptosis-inducing ligand receptor 2, death domain containing receptor for TRAILApo-2L, tumor necrosis factor receptor-like protein ZTNFR9, p53-regulated DNA damage-inducible cell death receptor(killer)
Isotype/Mimetic
Human IgG
Animal-Derived Biomaterials Used
None
Sequence Available
No
Original Discovery Method
Human-derived phage display
Original Discovery Information Provided On Datasheet
No
Antibody/Binder Origins
Animal-free discovery, In vitro recombinant expression